Thermo Fisher Scientific Highlights Innovations in Clinical Research and Specialty Diagnostics at AACC 2010
Simplified Workflow for Immunosuppressant Analysis Saves Time and Improves Results
WALTHAM, Mass., Jul 26, 2010 (BUSINESS WIRE) — Thermo Fisher Scientific Inc., the world leader in serving science, will highlight its innovative offering of products and services for clinical research and specialty diagnostics during the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo held in Anaheim, California, July 25 – 29, 2010.
Thermo Fisher will introduce a substantially improved liquid chromatography/mass spectrometry (LC/MS) workflow for immunosuppressant analysis designed to improve productivity in clinical research applications. The seamless integration of instruments, software, consumables and reagents significantly reduces sample preparation time, improves overall performance and provides a total workflow supported by a single supplier. This workflow will be adapted to the analysis of a number of drugs, as well as vitamins and steroids. For more information, visit Booth 2415 at the Anaheim Convention Center.
“This year at AACC, we are highlighting how our scale and depth of capabilities are meeting increasing demand in clinical research and specialty diagnostics markets,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “Building on the strength of our highly recognized brands for clinical research and combining them into an easy-to-use workflow demonstrates for our customers the benefit of working with a single, comprehensive supplier.”
Thermo Fisher’s focus at this year’s AACC meeting is on advancements in both sample preparation and analysis. The company’s innovative workflow combines automated sample preparation, a fully contained immunosuppressant test kit, as well as industry-leading LC/MS technology and columns specifically designed for clinical research.
The Thermo Scientific ClinSpec Immunosuppressant Test Kit, for example, provides all the reagents, standards, controls and sample preparation methodology needed to monitor immunosuppressant drugs during research. The kit is part of a total solution for immunosuppressant drug analysis and was developed to provide significant time savings when compared with manual sample preparation. Similarly, the Thermo Scientific Versette automated liquid-handling platform is used to simplify the sample-handling method, whether the research chemist is transitioning from handheld pipetting or establishing an integrated system.
For more information about Thermo Fisher’s products and services for clinical research and specialty diagnostics, visit www.thermofisher.com/aacc2010.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. /quotes/comstock/13*!tmo/quotes/nls/tmo (TMO 46.24, +0.07, +0.15%) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com
